CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
|Videos|October 27, 2021
Asembia 2021: Steve Peskin of Horizon BCBS of NJ Talks Value-Based Contracting Between Payers & Pharma Companies
Author(s)Laura Joszt, MA
Steve Peskin of Horizon BCBS of NJ, executive medical director of Population Health at Horizon Blue Cross Blue Shield of New Jersey, shares forms of value-based contracting between payers and pharmaceutical companies.
Advertisement
Advertisement
Related to this article
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
3
The Future of Employer Health Benefits Is Connected Care
4
Jeff Dunn, Pharm.D., MBA, on how PBMs and payers can respond to ‘340B rebate erosion’ | PBMI 2026
5